CompareBiovertisvsOnyvax
Customers evaluate the quality ofBiovertis's products using the following success metrics.
Overview
Biovertis is based in Austria
Biovertis discovers and develops antibiotics to combat the increasing threat of infective microbes that are resistant to available therapies.
Onyvax is based in United Kingdom
Onyvax is developing new cancer therapies that harness the selective power of the immune system to seek out and destroy tumor cells. Onyvax's products specifically target cancer cells, increasing the likelihood that they will be effective while minimising side effects associated with many conventional treatments. These therapies can broadly be classed as therapeutic cancer vaccines. Onyvax's lead product is in clinical trials for the treatment of prostate cancer and is poised to enter the final stages of development. Onyvax is committed to the commercialisation of therapies that enhance survival while maintaining a high quality of life for patients. The Company is based in London and has collaborations with leading hospitals and other institutions throughout Europe and the US.
Demo Video
領導
Thomas Kapsner(Chief Executive Officer)
Peter Smith(Founder)
Product
Benefits
Products
Customers
Known Partners
Why They Buy
Information not available becauseBiovertishas not claimed their profile.
Work forBiovertis? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work forBiovertis?
Claim your profile now.
Information not available becauseOnyvaxhas not claimed their profile.
Work forOnyvax? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work forOnyvax?
Claim your profile now.